GURUFOCUS.COM » STOCK LIST » USA » NAS » HilleVax Inc (NAS:HLVX) » Definitions » Financial Strength
Switch to:

HilleVax Financial Strength

: 5 (As of Dec. 2021)
View and export this data going back to 2022. Start your Free Trial

HilleVax has the Financial Strength Rank of 5.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

HilleVax did not have earnings to cover the interest expense. As of today, HilleVax's Altman Z-Score is 0.00.


Competitive Comparison

For the Biotechnology subindustry, HilleVax's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

HilleVax Financial Strength Distribution

For the Biotechnology industry and Healthcare sector, HilleVax's Financial Strength distribution charts can be found below:

* The bar in red indicates where HilleVax's Financial Strength falls into.



HilleVax Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

HilleVax's Interest Expense for the months ended in Dec. 2021 was $-2.84 Mil. Its Operating Income for the months ended in Dec. 2021 was $-15.77 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $0.15 Mil.

HilleVax's Interest Coverage for the quarter that ended in Dec. 2021 is

HilleVax did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

HilleVax's Debt to Revenue Ratio for the quarter that ended in Dec. 2021 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2021 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(158.308 + 0.153) / 0
=N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

HilleVax has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HilleVax  (NAS:HLVX) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

HilleVax has the Financial Strength Rank of 5.


HilleVax Financial Strength Related Terms

Thank you for viewing the detailed overview of HilleVax's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


HilleVax Business Description

HilleVax logo
Traded in Other Exchanges
N/A
Address
Website
Executives
Fhmls X, L.l.c. 10 percent owner 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101
Dubin Gary director C/O HILLEVAX, INC. 75 STATE STREET, SUITE 100 - #9995 BOSTON MA 02109
Borkowski Astrid officer: Chief Medical Officer C/O HILLEVAX, INC. 75 STATE STREET, SUITE 100 - #9995 BOSTON MA 02109
Sepulveda Jaime director C/O HILLEVAX INC. 75 STATE STREET 100 - #9995 BOSTON MA 02109
Takeda Vaccines, Inc. 10 percent owner 75 SIDNEY STREET CAMBRIDGE MA 02139
Chu Shelley director ONE WINTHROP SQUARE SUITE 400 BOSTON MA 02110
Silbermann Susan Michele director C/O LIANBIO 103 CARNEGIE CENTER DRIVE, SUITE 215 PRINCETON NJ 08540
Fhmls X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101
Frazier Life Sciences X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101
Gerberding Julie L. director 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033
Kohli Aditya director, officer: Chief Operating Officer C/O PHATHOM PHARMACEUTICALS, INC. 2150 E. LAKE COOK ROAD, SUITE 800 BUFFALO GROVE IL 60089
Socks David A officer: CFO & Chief Business Officer C/O CADENCE PHARMACEUTICALS, INC. 12481 HIGH BLUFF DRIVE, SUITE 200 SAN DIEGO CA 92130
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO M0 103-8668
Hershberg Robert director, officer: President and CEO 3005 FIRST AVENUE SEATTLE WA 98121
Topper James N 10 percent owner 550 HAMILTON AVENUE, SUITE 100 PALO ALTO CA 94301
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)